Aurinia Pharmaceuticals Up Nearly 14%, on Pace for Largest Percent Increase Since January 2023 -- Data Talk
Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options
Aurinia Pharmaceuticals(AUPH.US) Director Buys US$10.82 Million in Common Stock
$Aurinia Pharmaceuticals(AUPH.US)$ Director TANG KEVIN purchased 1.2 million shares of common stock on Dec 5, 6, 9, 2024 at an average price of $9.02 for a total value of $10.82 million.Source:
Aurinia Pharmaceuticals Insider Bought Shares Worth $10,822,000, According to a Recent SEC Filing
Kevin Tang Buys $10.82 Million in Aurinia Pharmaceuticals Shares
While Institutions Own 40% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), Retail Investors Are Its Largest Shareholders With 52% Ownership
Improved Revenues Required Before Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock's 27% Jump Looks Justified
Insiders At Aurinia Pharmaceuticals Sold US$2.0m In Stock, Alluding To Potential Weakness
Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH) and Siemens Healthineers AG (OtherSEMHF)
Aurinia Pharmaceuticals Celebrates New Lupus Nephritis Guidelines
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
Express News | Aurinia Commends 2024 Updated Acr Guidelines for Screening, Treatment, and Management of Lupus Nephritis
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS in Managing LN at American College of Rheumatology Convergence 2024
Express News | Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of Lupkynis® in Managing Ln at American College of Rheumatology Convergence 2024
Aurinia to Participate in Jefferies London Healthcare Conference
RBC Capital Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Raises Target Price to $9
Bloom Burton Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Raises Target Price to $10.85
Positive Outlook on Aurinia Pharmaceuticals Amid Strong Financial Performance and Strategic Cost Management
Leerink Partners Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating
Aurinia Pharmaceuticals Reports Strong Growth and Strategic Restructuring